Simon

Investment Committee

Simon Michel is the CEO of Ypsomed, the leading developer of self-injection systems for treatment of chronic disease.  He also chairs the board of the DCB, a global center for diabetes technology innovation that transforms diagnosis and treatment and improves quality of life, and has held various other board, trustee and advisory roles including at Unitectra, sitem-insel, Forster Rohner, LEM Surgical and Swiss Medtech.

Cookies

This website is using necessary cookies to provide a good browsing experience, see our Cookie Policy. These include essential cookies that are necessary for the operation of the siteor for comfort settings.

Cookies

This website is using necessary cookies to provide a good browsing experience, see our Cookie Policy. These include essential cookies that are necessary for the operation of the siteor for comfort settings.

Your cookie preferences have been saved.